跳至主要内容
临床试验/NCT00079248
NCT00079248Unknown不适用

UK Trial Of Hormone Replacement Therapy (HRT) In Women With A History Of Early Stage Breast Cancer

Institute of Cancer Research, United Kingdom2 个研究点 分布在 1 个国家开始时间: 2002年3月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
发起方
试验地点
2

研究概览

简要总结

RATIONALE: Hormone replacement therapy may be effective in relieving symptoms of menopause, such as hot flashes, night sweats, and vaginal dryness, without causing a recurrence of breast cancer.

PURPOSE: This randomized clinical trial is studying hormone replacement therapy to see how well it works in relieving symptoms of menopause in postmenopausal women with previous stage I or stage II breast cancer.

详细描述

OBJECTIVES:

  • Compare disease-free survival and overall survival of postmenopausal women with prior stage I or II breast cancer treated with hormone replacement therapy (HRT) vs nonhormonal alternatives to HRT.
  • Compare relief of menopausal symptoms and quality of life of patients treated with these regimens.
  • Compare cardiovascular and osteoporotic events in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, age (< 40 years vs ≥ 40 years), and years from diagnosis (≤ 2 vs > 2 to < 5 vs ≥ 5). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral or transdermal HRT comprising estrogen with or without progesterone for at least 2 years.
  • Arm II: Patients are offered advice on nonhormonal HRT alternatives. Menopausal symptoms are assessed at baseline, at 3, 6, and 12 months, every 6 months for 4 years, and then annually thereafter. Quality of life is assessed at baseline, at 3, 6, and 12 months, every 6 months for 1 year, and then annually thereafter.

Patients are followed every 6 months for 3 years and then annually thereafter.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Supportive Care

入排标准

性别
Female
接受健康志愿者

入选标准

  • DISEASE CHARACTERISTICS:
  • Prior diagnosis of stage I or II breast cancer
  • No clinical evidence of recurrence
  • Meets criteria for 1 of the following:
  • Amenorrheic for at least the past 6 months
  • Radiotherapy- or chemically-induced ovarian suppression allowed
  • Prior surgical bilateral oophorectomy
  • Experiencing vasomotor symptoms (i.e., hot flashes or night sweats) with or without vaginal dryness
  • No undiagnosed postmenopausal bleeding
  • No ductal carcinoma in situ or lobular carcinoma in situ alone
  • Hormone receptor status:
  • Not specified
  • PATIENT CHARACTERISTICS:
  • Postmenopausal
  • Menopausal status
  • Postmenopausal
  • Performance status
  • Not specified
  • Life expectancy
  • Not specified
  • Hematopoietic
  • Not specified
  • No severe, active liver disease with abnormal liver function tests
  • No acute, intermittent porphyria
  • Fibrinolysis and coagulation normal
  • Not specified
  • Cardiovascular
  • No prior deep vein thrombosis
  • Thrombophlebitis or superficial phlebitis alone allowed
  • No prior retinal vein thrombosis
  • No prior pulmonary embolism
  • Not pregnant
  • No prior alcohol, drug, or chemical abuse
  • No other prior or concurrent malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • Not specified
  • Chemotherapy
  • No concurrent chemotherapy
  • Endocrine therapy
  • More than 3 months since prior oral or transdermal hormone replacement therapy (HRT)
  • More than 5 years since prior HRT implant
  • No other concurrent HRT
  • No concurrent gonadotropin-releasing hormone agonists (e.g., goserelin) if less than 2 years of planned treatment remains
  • No other concurrent low-dose progestins
  • No concurrent tibolone
  • No concurrent phytoestrogens (e.g., black cohosh, red clover, or soy)
  • Radiotherapy
  • See Disease Characteristics
  • See Disease Characteristics
  • 另有 1 项未显示

排除标准

  • 未提供

研究者

发起方
Institute of Cancer Research, United Kingdom
申办方类型
Other

研究点 (2)

Loading locations...

相似试验